Global

Pancreatic Cancer Gets a New Radiation Rulebook

Myeloma Gets an Accelerated Approval. The Endpoint Is the Politics.

Parkinson’s Gets Fast Track, Not Fast Proof

ctDNA Is Becoming a Surveillance Policy, Not Just a Test

AI Wants to Choose Pancreatic Chemo

Oral GLP-1 drugs could widen access, but high prices may do the opposite

GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?

Boehringer Ingelheim is adding a third target to obesity treatment.

Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
